Therapeutic Advances in Hematology

Papers
(The median citation count of Therapeutic Advances in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias37
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib36
Bortezomib in autoimmune hemolytic anemia and beyond27
Venetoclax-containing regimens in acute myeloid leukemia27
Current evidence and the emerging role of eltrombopag in severe aplastic anemia27
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies26
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria22
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review20
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data19
The potential of pirtobrutinib in multiple B-cell malignancies19
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)19
Primary central nervous system lymphoma in the United States, 1975–201719
International consensus recommendations on the management of people with haemophilia B18
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy18
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor18
Current and emerging treatment options in primary mediastinal B-cell lymphoma16
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia16
Current state of CAR-T therapy for T-cell malignancies15
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma15
MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy15
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria15
Advances in therapeutic options for newly diagnosed, high-risk AML patients14
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data14
The role of tazemetostat in relapsed/refractory follicular lymphoma13
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective13
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia13
The role of carfilzomib in relapsed/refractory multiple myeloma13
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia13
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study13
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma13
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications13
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)12
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers12
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy12
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma12
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study10
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma10
Mantle cell lymphoma management trends and novel agents: where are we going?10
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation10
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations10
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma9
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma9
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia9
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study9
The role of acalabrutinib in adults with chronic lymphocytic leukemia9
Acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration9
Emicizumab in acquired haemophilia A: about two clinical cases and literature review9
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)8
Outpatient allogeneic hematopoietic stem-cell transplantation: a review8
Update on the role of copanlisib in hematologic malignancies8
Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol8
How to translate and implement the current science of gene therapy into haemophilia care?8
The use of tafasitamab in diffuse large B-cell lymphoma8
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)8
Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation8
Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide7
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study7
Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist7
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND7
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report7
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-int7
Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors7
Prophylactic management of patients with von Willebrand disease7
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma7
Treosulfan-based conditioning for inborn errors of immunity7
Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens7
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma6
Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study6
Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies6
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia6
Considerations for shared decision management in previously untreated patients with hemophilia A or B6
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain6
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia6
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors6
Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis6
Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia6
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?6
Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation5
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis5
Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe ap5
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma5
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study5
Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation5
Zanubrutinib in lymphoproliferative disorders: a comprehensive review5
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study5
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib5
Gene therapy in haemophilia: literature review and regional perspectives for Turkey4
Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma4
Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study4
Changing paradigms of hemophilia care across larger specialized treatment centers in the European region4
Iron overload status in patients with non-transfusion-dependent thalassemia in China4
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from4
Efgartigimod alfa for the treatment of primary immune thrombocytopenia4
Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report4
Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report4
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?4
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States4
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments4
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond4
Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma4
Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome4
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations4
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review4
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase4
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry3
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia3
The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study3
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma3
Anemia is associated with long-term exposure to PM2.5 and its components: a large population-based study in Southwest China3
A 10-fold and greater increase in D-dimer at admission in COVID-19 patients is highly predictive of pulmonary embolism in a retrospective cohort study3
Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome3
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente3
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report3
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study3
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study3
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China3
Role of abatacept in the prevention of graft-versus-host disease: current perspectives3
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges3
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality3
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study3
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome3
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells3
0.031183004379272